Home » Stocks » Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (TAK)

Stock Price: $18.49 USD -0.06 (-0.32%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $18.51 +0.02 (0.11%) Aug 14, 4:25 PM

Stock Price Chart

Key Info

Market Cap 57.80B
Revenue (ttm) 30.89B
Net Income (ttm) 415.19M
Shares Out 3.15B
EPS (ttm) 0.81
PE Ratio 22.83
Forward PE 15.08
Dividend $0.84
Dividend Yield 4.54%

Stock Quote

Trading Day Aug 14, 2020
Last Price $18.49
Previous Close $18.55
Change ($) -0.06
Change (%) -0.32%
Day's Open 18.53
Day's Range 18.46 - 18.57
Day's Volume 498,004
52-Week Range 12.43 - 20.93

More Stats

Market Cap 57.80B
Enterprise Value 104.11B
Earnings Date (est) Oct 28, 2020
Ex-Dividend Date Mar 30, 2020
Shares Outstanding 3.15B
Float 3.09B
EPS (basic) n/a
EPS (diluted) 0.81
FCF / Share 2.18
Dividend $0.84
Dividend Yield 4.54%
Earnings Yield 4.38%
FCF Yield 12.70%
Payout Ratio n/a
Shares Short 2.03M
Short Ratio 2.63
Short % of Float n/a
Beta 1.09
PE Ratio 22.83
Forward PE 15.08
P/FCF Ratio 7.88
PS Ratio 1.87
PB Ratio 1.28
Revenue 30.89B
Operating Income 942.30M
Net Income 415.19M
Free Cash Flow 7.34B
Net Cash -46.31B
Net Cash / Share n/a
Gross Margin 66.89%
Operating Margin 3.05%
Profit Margin 1.30%
FCF Margin 23.76%
ROA 1.45%
ROE 2.50%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (14)

Buy 10
Overweight 2
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$24.85*
(34.40% upside)
Low
19.3
Current: $18.49
High
30.6
Target: 24.85
*Average 12-month USD price target from 13 stock analysts.

Financial Performance

Financial numbers in millions JPY.

Financial Overview

Year2019201820172016
Revenue3,291,1882,097,2241,770,5311,732,051
Revenue Growth56.93%18.45%2.22%-
Gross Profit2,201,4241,445,4951,274,6101,173,296
Operating Income100,408237,685241,789155,867
Net Income44,241135,192186,886114,940
Shares Outstanding1,6831,683--
Earnings Per Share14.1369.91118.7873.13
EPS Growth-79.8%-41.14%62.42%-
Dividend Per Share--0.811.19
Dividend Growth---32.27%-
Operating Cash Flow896,520373,388407,737302,114
Capital Expenditures-114,504-26,960-64,040-59,031
Free Cash Flow782,016346,428343,697243,083
Cash & Equivalents653,436725,369375,1680.00
Total Debt5,588,1396,038,3661,106,498-
Net Cash / Debt-4,934,703-5,312,997-731,3300.00
Assets12,821,09413,792,7734,106,463-
Liabilities8,093,6088,606,7822,089,054-
Book Value4,723,4835,181,9851,997,424-
Numbers in millions JPY, except per-share numbers.

Company Profile

Company Details

Full Name Takeda Pharmaceutical Company Limited
Country Japan
Employees 47,495
CEO Christophe Weber

Stock Information

Ticker Symbol TAK
Stock Exchange New York Stock Exchange
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSE: TAK

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS to uncover novel tumor-specific regulatory t-cell targets and develop unique anti-suppressor-based immunotherapies; a strategic partnership with Neurocrine Biosciences, Inc. to develop and commercialize therapies for psychiatric disorders; and Carmine Therapeutics to discover, develop, and commercialize transformative non-viral gene therapies for two rare diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.